ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 Phase 3 GLOW Study: Residual Disease Kinetics Among CLL Patients With High-Risk Factors Treated With 1L Fixed-Duration Ibr + Ven vs. Clb + Obi
By
ASH 2022 Conference Coverage
FEATURING
Carsten Utoft Niemann
By
ASH 2022 Conference Coverage
FEATURING
Carsten Utoft Niemann
44 views
December 22, 2022
Login to view comments.
Click here to Login
Leukemia